# Dermata Therapeutics, Inc.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/Dermata Therapeutics, Inc.).

## Overview

Dermata Therapeutics, Inc. is a U.S.-based clinical-stage pharmaceutical company focused on developing dermatology products, including XYNGARI™ and DMT410, with a recent shift toward OTC acne kits and other skin-condition applications. The company has no approved products or product revenue to date and is still building the regulatory, manufacturing, and commercial infrastructure needed to launch products.

## Products & services

• XYNGARI™ topical dermatology product candidate
• DMT410 topical botulinum toxin program
• OTC acne kit development and commercialization
• Spongilla-based technology platform
• Clinical development for hyperhidrosis and skin conditions

- **Prescription and clinical-stage dermatology candidates** (60%) — Includes XYNGARI™ and related clinical programs being developed for acne and other skin conditions.
- **OTC acne products** (25%) — Includes planned over-the-counter acne kits intended for consumer retail and digital channels.
- **Botulinum toxin and aesthetic skin programs** (10%) — Includes DMT410 and related applications for aesthetic and medical dermatology uses.
- **Platform and collaboration activities** (5%) — Includes technology platform development, clinical collaborations, and licensing-related work.

- XYNGARI™ topical product candidate for acne and related dermatology uses
- DMT410 topical botulinum toxin program for aesthetic and medical skin conditions
- OTC acne kits designed for over-the-counter consumer use
- Spongilla technology platform underlying product development
- Clinical trial collaborations, including hyperhidrosis studies

## Customers

Dermata’s direct customers are not yet commercial end users, because the company has no approved products and no product sales. Its future buyers are expected to include consumers seeking OTC acne treatments, clinics and professionals using dermatology products, and potentially retail or e-commerce channel partners that distribute the products.

- **OTC acne consumers** (primary) — Consumers who would buy OTC acne kits for convenient self-treatment through retail or digital channels.
- **Dermatology clinics and professionals** (secondary) — Clinics and practitioners that may use or recommend topical dermatology products in professional settings.
- **Retail and e-commerce channel partners** (primary) — Distributors, retailers, and online channels that would carry and market the company’s OTC products.
- **Clinical trial participants** (secondary) — Patients enrolled in studies for acne, hyperhidrosis, and other skin-condition programs.
- **Strategic collaborators** (secondary) — Partners such as Revance that support clinical development, validation, or future commercialization.

- Consumers buying OTC acne kits for self-treatment
- Dermatology clinics and professionals for topical treatment use
- Retail and e-commerce partners that distribute OTC products
- Potential collaborators or licensees in dermatology and aesthetics
- Patients in clinical trials for acne and hyperhidrosis programs

## Geography

Dermata is headquartered in the United States and its disclosed clinical activity is concentrated there, including a Phase 2a hyperhidrosis study enrolling patients across U.S. sites. The company also references international competition and global supply-chain exposure, but its current operating footprint appears primarily U.S.-based.

- Headquartered in the United States
- Clinical trial sites disclosed in the U.S.
- Commercial plans currently centered on U.S. OTC pathways
- Supply chain and distribution may involve third-party vendors
- International competition and trade policy can affect costs

## Strategy

Dermata is pivoting from an Rx development model toward OTC pathways, with a focus on acne kits and related dermatology products that may be faster and cheaper to commercialize. Near term, the company is trying to preserve cash, complete development work, and secure additional capital or collaborations to fund clinical, regulatory, and launch activities.

- **OTC acne commercialization** (short-term) — OTC pathways may reduce regulatory complexity and manufacturing cost versus Rx development.
- **Capital preservation and financing** (short-term) — The company has recurring losses and a going-concern risk, so funding is required to continue operations.
- **Clinical and regulatory execution** (medium-term) — Successful trials and regulatory pathway selection are needed to support product launch and value creation.
- **Manufacturing and supply-chain buildout** (medium-term) — Commercialization depends on compliant manufacturing and reliable third-party supply chains.

- Shift product strategy from Rx development to OTC commercialization
- Advance XYNGARI™-based acne products toward launch readiness
- Continue DMT410 development for aesthetic and medical skin conditions
- Use collaborations to reduce development and commercialization burden
- Raise additional capital to fund trials, manufacturing, and launch

## Risks

Dermata is a pre-revenue biotech with substantial financing risk, regulatory execution risk, and dependence on third-party manufacturing and distribution. Its shift to OTC pathways adds uncertainty around approvals, labeling, reformulation, and counterfeit exposure, while its small scale makes it vulnerable to cash burn and supply-chain disruptions.

- **Insufficient financing and going-concern risk** [critical] — The company has recurring losses, limited cash runway, and needs more capital to fund development and launch plans.
- **OTC regulatory pathway uncertainty** [high] — Moving from Rx to OTC monograph or OTC NDA pathways can require reformulation, relabeling, or additional studies.
- **Third-party manufacturing and supply-chain dependence** [high] — The company relies on external manufacturers and logistics providers for clinical and commercial supply.
- **Counterfeit and unauthorized products** [medium] — OTC products can be copied or sold through unauthorized channels, harming consumers and brand trust.
- **Competition from private label and established brands** [medium] — OTC dermatology products compete against heavily marketed brands and lower-priced retailer labels.

- Going-concern risk if additional capital is not raised
- OTC regulatory pathway may delay or block launches
- Third-party manufacturing and distribution disruptions
- Dependence on unapproved product candidates for future revenue
- Counterfeit or infringing OTC products could damage trust
- Competition from lower-cost private label and branded products

## Accounting

Dermata’s accounting is dominated by R&D expense estimation, clinical development accruals, and stock-based compensation in a pre-revenue setting. Because the company has no product sales, reported results are highly sensitive to trial timing, manufacturing spend, and whether prepaid external costs are expensed or capitalized as services are received.

- **Research and development expense estimation** — Can materially change quarterly operating loss
- **Prepaid external development costs** — Creates quarter-to-quarter volatility in R&D
- **Stock-based compensation** — Affects reported losses and dilution analysis
- **Going-concern assessment** — Signals financing dependence and survival risk

- R&D accruals depend on clinical and manufacturing timing
- Prepaid research services are capitalized until received
- Stock-based compensation affects operating expense levels
- No product revenue means losses are driven by development spend
- Going-concern disclosure reflects cash runway assumptions

---

*Last updated: 2026-04-28T20:01:43.061191+00:00*